Zambon Taps Kinaxis to Enhance Transparency Across Global Supply Chain
Italian multinational pharmaceutical company seeks to gain clarity amid complexity following product portfolio expansion
With 23 subsidiaries, a product presence in 87 countries and manufacturing facilities spread across three continents, the complexity of the Italian-headquartered company’s supply chain requires a unique approach to balance its supply and demand.
Alongside its three historical therapeutic areas of focus targeting respiratory system diseases, urinary tract infections and pain management, Zambon has expanded its portfolio in recent years by introducing important treatments for Parkinson’s, Cystic Fibrosis and developing a pipeline focused on rare diseases such as Bronchiolitis Obliterans Syndrome (BOS) and Non–Cystic Fibrosis Bronchiectasis (NCFB). Each of which involves a high-touch approach to adequately balance production resources and inventory levels based on distinct logistics parameters including lead times and safety stock. Kinaxis Maestro™, the only AI-infused supply chain orchestration platform, will enable the pharmaceutical company to refine its sales and operations planning processes and gain a better handle on its supply chain, even during periods of demand volatility or disruption.
“We’re thrilled to be working with
“With a dizzying array of stakeholders including manufacturers, distributors, wholesalers, regulators, doctors and pharmacies, drug supply chains are about as complex as they come,” said Fabienne Cetre, executive vice president, EMEA sales at
With the addition of Zambon to its growing customer base,
Kinaxis’ AI-powered software allows companies to orchestrate their supply chain network end to end, from strategic planning to last-mile delivery. Kinaxis’ technology helps companies that supply the agricultural industry with 40% of the world’s tractors, that keep more than 110 billion teeth clean each year, and that ensures more than 35 million pets are fed nutritious meals each year.
To learn more about
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20240923380059/en/
Media Relations
jcook@kinaxis.com
289-552-4640
Investor Relations
rwadsworth@kinaxis.com
613-907-7613
Source: